LLY

1,052.84

+4.37%↑

JNJ

246.03

+1.46%↑

ABBV

228.33

+1.59%↑

NVS

164.74

+1.26%↑

MRK

123.15

+0.73%↑

LLY

1,052.84

+4.37%↑

JNJ

246.03

+1.46%↑

ABBV

228.33

+1.59%↑

NVS

164.74

+1.26%↑

MRK

123.15

+0.73%↑

LLY

1,052.84

+4.37%↑

JNJ

246.03

+1.46%↑

ABBV

228.33

+1.59%↑

NVS

164.74

+1.26%↑

MRK

123.15

+0.73%↑

LLY

1,052.84

+4.37%↑

JNJ

246.03

+1.46%↑

ABBV

228.33

+1.59%↑

NVS

164.74

+1.26%↑

MRK

123.15

+0.73%↑

LLY

1,052.84

+4.37%↑

JNJ

246.03

+1.46%↑

ABBV

228.33

+1.59%↑

NVS

164.74

+1.26%↑

MRK

123.15

+0.73%↑

Home・Akcijų sąrašas・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

429.9 -1.59

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

424.87

Max

436.84

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-72M -114M
Pardavimai	74M 287M
Pelno marža	-39.75
Darbuotojai	528
EBITDA	-68M -106M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+59.74% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-04-30

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1.4B 11B
Ankstesnė atidarymo kaina	431.49
Ankstesnė uždarymo kaina	429.9

Naujienos nuotaikos

By Acuity

50%

141 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

263.2 / 277.1 Palaikymas ir pasipriešinimas

Madrigal Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-22 23:55; UTC

Rinkos pokalbiai

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

2026-02-22 23:53; UTC

Rinkos pokalbiai

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

2026-02-22 23:53; UTC

Rinkos pokalbiai

Key China Rates Likely to Be Held Steady for Now -- Market Talk

2026-02-22 23:51; UTC

Rinkos pokalbiai

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

2026-02-22 23:35; UTC

Rinkos pokalbiai

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

2026-02-22 23:21; UTC

Uždarbis

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

2026-02-22 23:20; UTC

Uždarbis

Nickel Industries 2025 Operating Profit US$126.4 Million

2026-02-22 23:19; UTC

Uždarbis

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

2026-02-22 23:19; UTC

Uždarbis

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

2026-02-22 23:18; UTC

Uždarbis

Nickel Industries Won't Pay a Final Dividend

2026-02-22 23:16; UTC

Uždarbis

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

2026-02-22 21:35; UTC

Uždarbis

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

2026-02-22 21:34; UTC

Uždarbis

Ampol Says F&I Australia, International Have Begun 2026 Strongly

2026-02-22 21:34; UTC

Uždarbis

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

2026-02-22 21:33; UTC

Uždarbis

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

2026-02-22 21:33; UTC

Uždarbis

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

2026-02-22 21:28; UTC

Uždarbis

Ampol Final Dividend A$0.60/Share

2026-02-22 21:28; UTC

Uždarbis

Ampol FY Revenue A$31.37 Billion, Down 10%

2026-02-22 21:28; UTC

Uždarbis

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

2026-02-22 21:28; UTC

Uždarbis

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

2026-02-21 14:31; UTC

Įsigijimai, susijungimai, perėmimai

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

2026-02-21 05:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-02-20 23:12; UTC

Įsigijimai, susijungimai, perėmimai

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

2026-02-20 22:12; UTC

Uždarbis

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

2026-02-20 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-20 21:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-02-20 21:23; UTC

Uždarbis

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

2026-02-20 21:20; UTC

Rinkos pokalbiai

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

2026-02-20 21:01; UTC

Įsigijimai, susijungimai, perėmimai

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

2026-02-20 20:38; UTC

Rinkos pokalbiai

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Akcijų palyginimas

Kainos pokytis

Madrigal Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

59.74% į viršų

12 mėnesių prognozė

Vidutinis 694.9 USD 59.74%

Aukščiausias 964 USD

Žemiausias 529 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Madrigal Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

11 ratings

Pirkti

Laikyti

Parduoti

Remiantis 11 analitikų, pateikusių Madrigal Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

263.2 / 277.1Palaikymas ir pasipriešinimas

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Rinkos nuotaikos

By Acuity

141 / 351 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.